Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 733-741

  Gilli, Francesca ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; JANUS KINASE 1; NEUTRALIZING ANTIBODY; PROTEIN KINASE TYK2;

ALTERNATIVE RNA SPLICING; ANTIGEN BINDING; BINDING AFFINITY; DRUG EFFICACY; DRUG INHIBITION; EXON; GENE EXPRESSION; HUMAN; LIGAND BINDING; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE;

GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROTEIN ISOFORMS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 77957333021     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0098     Document Type: Review

References (73)

1. Abramovich C, Ratovitski E, Lundgren E., Revel M. 1994. Identification of mRNAs encoding two different soluble forms of the human interferon-alpha receptor. FEBS Lett '338(3):295-300.
2. Bertolotto A, Gilli F, Sala A., Capobianco M, Malucchi S, Milano E., Melis F, Marnetto F, Lindberg RLP, Bottero R, Di Sapio A, Giordana MT. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology '60:634-639.
3. Billard C, Ferbus D, Diez R.A., Kolb JP, Mathiot C, Belanger C, Auzanneau G., Varet B, Falcoff E, Dumont J. 1991. Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: lack of in vivo down-regulation and reduced affinity of IFN-alpha receptors in unresponsive patients. Leuk Res '15:121-128.
4. Borden, EC, Sen GC, Uzè G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine [Review]. Nat Rev Drug Discov 6(12):975-990.
5. Branca AA, Faltynek CR, D'Alessandro SB, Baglioni C. 1982. Interaction of interferon with cellular receptors: internalization and degradation of cell-bound interferon. J Biol Chem '257:13291-13296.
6. Brierley MM, Fish EN 2002. IFNα/β receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res '22:835-845.
7. Cajean-Feroldi C., Nosal F, Nardeux P.C., Gallet X., Guymarho J, Baychelier F, Sempe P., Tovey MG, Escary JL, Eid P. 2004. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry '43:12498-12512.
8. Cleveland MG, Lane RG, Klimpel GRR. 1987. Enhanced IFN-α/β and defective IFN-β production in chronic GVHD: a potential mechanism for immunosuppression. Cell Immunol '110:120-130.
9. Cohen B, Novick D, Barak S., Rubinstein M. 1995. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol '15(8):4208-4214.
10. Colamonici O, Yan H, Domanski P. 1994. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol Cell Biol '14:8133-8142.
11. Comabella M, Lünemann JD, Rio J., Sànchez A, Lopez C., Julia E, Fernandez M, Nonell LL, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. 2009. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132(PART 12):3353-3365.
12. Cook JR, Cleary CM, Mariano T.M., Izotova L., Pestka S. 1996. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J Biol Chem '271(23):13448-13453.
13. Cutrone EC, Langer JA 2001. Identification of critical residues in bovine IFNAR-1 responsible for interferon binding. J Biol Chem '276:17140-17148.
14. Deisenhammer F, Reindel M, Harvey J., Gasse T, Dilitz E, Berger T. 1999. Bioavailability of interferon-beta 1b in MS patients with and without neutralizing antibodies. Neurology '52:1239-1243.
15. de Weerd N.A., Samarajiwa SA, Hertzog PJ 2007. Type I interferon receptors: biochemistry and biological functions. J Biol Chem '282:20053-20057.
16. Domanski P, Colamonici OR 1996. The type-I interferon receptor. The long and short of it [Review]. Cytokine Growth Factor Rev '7(2):143-151.
17. Dupont SA, Goelz S, Goyal J., Green M. 2002. Mechanisms for regulation of cellular responsiveness to human IFNβ 1a. J Interferon Cytokine Res '22:491-501.
18. Durelli L, Conti L, Clerico M., Borselli D, Contessa G, Ribellino P., Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-b. Ann Neurol '65(5):499-509.
19. Eantuzzi L, Eid P, Malorni W., Rainaldi G, Gauzzi MC, Pellegrini S, Belardelli F., Gessani S. 1997. Post-translational up-regulation of the cell surface-associated component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon. Eur J Immunol '27:1075-1081.
20. Francis GS, Rice GP, Alsop J.C., PRISMS Study Group. 2005. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology '65:48-55.
21. Gauzzi MG, Canini I, Eid P., Belardelli F, Gessani S. 2002. Loss of type I IFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells. J Immunol '169:3038-3045.
22. Gavutis M, Lata S, Lamken P., Muller P, Piehler J. 2005. Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection. Biophys J '88:4289-4302.
23. Gazziola C, Cordani N, Carta S., De Lorenzo E, Colombatti A, Perris R. 2005. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFN-alpha on pleomorphic sarcoma cells. Int J Oncol '26(1):129-140.
24. Gilli F, Bertolotto A, Sala A., Hoffmann F, Capobianco M, Malucchi S., Glass T, Kappos L, Lindberg RLP, Leppert D. 2004. Neutralizing antibodies against IFNβ in multiple sclerosis: antagonization of IFNβ mediated suppression of MMPs. Brain '127:259-268.
25. Gilli F, Marnetto F, Caldano M., Valentino P, Granieri L, Di Sapio A, Capobianco M, Sala A, Malucchi S, Kappos L, Lindberg RLP, Bertolotto A. 2007. Anti-interferon-β neutralising activity is not entirely mediated by antibodies. J Neuroimmunol '92:198-205.
26. Gilli F, Valentino P, Caldano M., Granieri L, Capobianco M, Malucchi S., Sala A, Marnetto F, Bertolotto A. 2008. Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis. Neurology '71(24):1940-1947.
27. Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A., King J, Metz L, Pardo G., Simsarian J, Sorensen PS, Stubinski B, the RNF Study Group. 2007. Immunogenicity and tolerability of an investigational formulation of interferon-beta 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther '29:1128-1145.
28. Hannigan GE, Fish EN, Williams BRG. 1984. Modulation of human interferon-γ receptor expression by human interferon-γ. J Biol Chem 259:8084-8086.
29. Hardy MP, Owczarek CM, Trajanovska S, Liu X., Kola I, Hertzog PJ 2001. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood '97(2):473-482.
30. The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology '43:655-661.
31. Ito K, Tanaka H, Ito T., Sultana TA, Kyo T, Imanaka F, Ohmoto Y., Kimura A. 2004. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol '73(3):191-205.
32. rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol '39:285-294.
33. Jaitin DA, Roisman, LC, Jaks E., Gavutis M, Piehler J, Van der, HJ, Uzè G, Schreiber G. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol '26:1888-1897.
34. Jaks E, Gavutis M, Uze G., Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol '366:525-539.
35. Jones SA, Richards PJ, Scheller J, Rose-John S. 2005. IL-6 trans-signalling: the in vivo consequences. J Interferon Cytokine Res '25(5):241-253.
36. Kappos L, Clanet M, Sandberg-Wollheim M, Radue E.W., Hartung HP, Hohlfeld R, Xu J, Bennet D., Sandrock A, Goelz S, the European Interferon Beta-1a IM Dose-Comparison Study Investigators. 2005. Neutralising antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology '65:40-47.
37. Karussis D, Biermann LD, Bohlega S, Boiko A., Chofflon M, Fazekas F, Freedman M., Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A, the International Working Group for Treatment Optimization in MS. 2006. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting [Review]. Eur J Neurol 13(1):61-71.
38. Kiessling LL, Gordon EJ 1998. Transforming the cell surface through proteolysis [Review]. Chem Biol 5(3):R49-R62.
39. Lamken P, Lata S, Gavutis M., Piehler J. 2004. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol '341:303-318.
40. Lau AS, Hannigan GE, Freedman M.H., Williamo BRG. 1986. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest '77:1632-1638.
41. Lutfalla G, Holland SJ, Cinato E, Monneron D., Reboul J, Rogers NC, Smith J.M., Stark GR, Gardiner K, Mogensen KE, Kerr IM, Uzè G. 1995. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J '14(20):5100-5108.
42. Malucchi S, Sala A, Gilli F., Bottero R, Di Sapio A, Capobianco M, Bertolotto A. 2004. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology '62:2031-2037. (Pubitemid 38738217)
43. Marijanovic Z, Ragimbeau J, van der Heyden J, Uzé G, Pellegrini S. 2007. Comparable potency of IFN-alpha2 and IFN-beta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J 407(1):141-151.
44. Mathurin P, Xiong S, Kharbanda K.K., Veal N., Miyahara T, Motomura K, Rippe R.A., Bachem MG, Tsukamoto H. 2002. IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol '282:G981-G990.
45. McKeage K, Wagstaff AJ 2007. Subcutaneous interferon-beta-1a: new formulation. CNS Drugs '21:871-876.
46. McKenna SD, Vergilis K, Arulanandam A.R., Weiser WY, Nabioullin R, Tepper MA 2004. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and anti-tumor activity in xenografted SCID mice. J Interferon Cytokine Res '24(2):119-129.
47. Perheentupa J, Husebye E, Kadota Y., Willcox N. 2006. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3:e289.
48. Novick D, Cohen B, Rubinstein M. 1994. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell '77(3):391-400.
49. Oliver B, Mayorga C, Fernandez V., Leyva L, Leon A, Luque G., Lopez JC, Tamayo JA, Pinto-Medel MJ, de Ramon E, Blanco E, Alonso A, Fernandez O. 2007. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol '183: 225-231.
50. Owczarek CM, Hwang SY, Holland K.A., Gulluyan LM, Tavaria T, Weaver B, Reich N.C., Kola I., Hertzog PJ. 1997. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem 272(38):23865-23870.
51. Pan M, Kalie E, Scaglione B.J., Raveche ES, Schreiber G, Langer JA 2008. Mutation of the IFNAR-1 receptor binding site of human IFN-R2 generates type I IFN competitive antagonists. Biochemistry '47:12018-12027.
52. Platanias LC. 2005. Introduction: interferon signals: what is classical and what is non-classical? J Interferon Cytokine Res 25(12):732.
53. Presky DH, Yang H, Minetti L.J., Chua AO, Nabavi N, Wu CY, Gately M.K., Gubler U. 1996. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA '93(24):14002-14007.
54. The PRISMS (Prevention of Relapses and Disability by Interferon-b-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology '56:1628-1636.
55. Río J., Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X. 2006. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol '59:344-352.
56. Rubinstein MP, Kovar M, Purton J.F., Cho JH, Boyman O, Surh CD, Sprent J. 2006. Converting IL-15 to a superagonist by binding to soluble IL-15Ra. Proc Natl Acad Sci USA '103(24):9166-9171.
57. Salomon I, Netzer N, Wildbaum G., Schif-Zuck S, Maor G, Karin N. 2002. Targeting the function of IFN-gamma inducible protein 10 suppress ongoing adjuvant arthritis. J Immunol '169:2685-2693.
58. Sandberg-Wollheim M., Bever C, Carter J., Farkkila M, Hurwitz B, Lapierre Y., Chang P, Francis GS, the EVIDENCE Study Group. 2005. Comparative tolerance of IFNβ 1a regimens in patients with relapsing remitting MS. The evidence study. J Neurol '252(1):8-13.
59. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov '1:457-462.
60. Serana F, Sottini A, Ghidini C., Zanotti C, Capra R, Cordioli C., Caimi L, Imberti L. 2008. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J Neuroimmunol '197:54-62.
61. Sherwood L. 1997. Human Physiology: From Cells to Systems, 3rd ed. Minneapolis (MN): West Publishing Co.
62. Sorensen PS, Deisenhammer F, Duda P., Hohlfeld R, Myhr KM, Palace J, Polman C., Pozzilli C, Ross C, for the EFNS Task Force on Anti-IFNβ Antibodies in Multiple Sclerosis. 2005. Guidelines on use of anti-IFNβ antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFNβ antibodies in multiple sclerosis. Eur J Neurol '12: 817-827.
63. Sundaresan S, Roberts PE, King K.L., Sliwkowski MX, Mather JP 1997. Biological response to ErbB ligands in non-transformed cell lines correlates with a specific pattern of receptor expression. Endocrinology '139:4756-4764.
64. Uings IJ, Farrow SN 2000. Cell receptors and cell signalling. Mol Path '53:295-299.
65. Uzé G, Luftalla G, Morgensen KE. 1995. α and β interferons and their receptors and their friends and relations. J Interferon Cytokine Res '15:3-26.
66. Uzé G, Schreiber G, Piehler J, Pellegrini S. 2007. The receptor of the type I interferon family [Review]. Curr Top Microbiol Immunol 316:71-95.
67. Vallittu AM, Halminen M, Peltoniemi J., Ilonen J, Julkunen I, Salmi A., Eralinna JP, the Finnish Beta-Interferon Study Group. 2002. Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology '58:1786-1790.
68. Vallittu AM, Salmi AA, Eralinna J.P., the Finnish Beta-Interferon Study Group. 2006. MxA protein induction in MS patients treated with intramuscular IFN-beta-1a. Neurol Sci '26(6):438-443.
69. Wildbaum G, Nahir MA, Karin N. 2003. Beneficial autoimmunity to pro-inflammatory mediators restrains the consequences of self-destructive immunity. Immunity '19:679-688.
70. Wildbaum G, Netzer N, Karin N. 2002. Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest '110:701-710.
71. Yan H, Krishnan K, Lim J.T., Contillo LG, Krolewski JJ 1996. Molecular characterization of an alpha interferon receptor 1 subunit (IFNAR1) domain required for TYK2 binding and signal transduction. Mol Cell Biol '16(5):2074-2082.
72. Youssef S, Maor G, Wildbaum G., Grabie N, Gour-Lavie A, Karin N. 2000. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest '106:361-371.
73. Zoon KC, Arnheiter H, Nedden D.Z., Fitzgerald DJP, Willingham MC 1989. Human interferon alpha enters cells by receptor-mediated endocytosis. Virology '130:195-203.